{"id":505087,"date":"2026-06-22T07:42:07","date_gmt":"2026-06-22T07:42:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/505087\/"},"modified":"2026-06-22T07:42:07","modified_gmt":"2026-06-22T07:42:07","slug":"3-asx-healthcare-shares-to-sell-despite-signs-of-sector-rebound","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/505087\/","title":{"rendered":"3 ASX healthcare shares to sell despite signs of sector rebound"},"content":{"rendered":"\n

Healthcare\u00a0shares<\/a>\u00a0are underperforming today, down 0.33%, while the benchmark S&P\/ASX 200 Index (ASX: XJO) is 0.15% lower.<\/p>\n

Healthcare led the\u00a011\u00a0market sectors\u00a0last week with a 4.84% rise<\/a> compared to a 0.28% lift for the ASX 200.<\/p>\n

The sector has been a poor performer over the past 12 months, down 39% overall amid many industry challenges<\/a>.<\/p>\n

These include US currency headwinds; three\u00a0interest rate<\/a>\u00a0rises in Australia; cost of living pressures leading people to delay procedures; higher shipping costs; new limits on insurance payouts in some nations; higher wage costs; and regulatory uncertainty in the US.<\/p>\n

However, things may be changing. <\/p>\n

On 3 June, the S&P\/ASX 200 Health Care Index\u00a0(ASX: XHJ) touched a 9-year low of 21,947.2 points. <\/p>\n

Since then, ASX 200 healthcare shares have lifted 12.8% while the broader ASX 200 has managed only a 0.37% gain. <\/p>\n

This may signal that a sector rebound has begun. <\/p>\n

Despite these green shoots, experts maintain sell ratings on several ASX 200 healthcare shares, as showcased on The Bull<\/a> this week. <\/p>\n

Let’s hear them out. <\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

The CSL share price is $114.30, down 1.6% today and down 52% over 12 months. <\/p>\n

Niv Dagan from Peak Asset Management has a sell rating on the market’s largest ASX 200 healthcare share.<\/p>\n

The expert commented:\u00a0<\/p>\n

A sell rating is justified as this biotechnology giant has materially downgraded its fiscal year 2026 outlook while announcing about $5 billion of additional non-cash pre-tax impairments across fiscal years 2026 and 2027. <\/p>\n

Revenue expectations have been reduced due to US immunoglobulin channel normalisation and weaker albumin prices in China.<\/p>\n

The CSL Vifor acquisition has under-performed. Also, government healthcare cost pressures and a higher interest rate environment present ongoing challenges for the biotechnology sector, further weighing on sentiment.<\/p>\n

The Cochlear share price is $117.55, down 0.5% today and down 60% over 12 months. <\/p>\n

Dagan also has a sell rating on this ASX 200 healthcare share.\u00a0<\/p>\n

He explained:\u00a0<\/p>\n

In April, the hearing implants maker materially reduced its fiscal year 2026 underlying net profit guidance to between $290 million and $330 million from between $435 million from $460 million in February. <\/p>\n

The downgrade was a response to weaker than expected demand in developed markets amid Middle East uncertainty, lower margins and foreign exchange headwinds. <\/p>\n

Hospital capacity constraints amid softer consumer sentiment and reduced referral activity are weighing on implant volumes, while cost base restructuring is likely to impact earnings in the near term.<\/p>\n

Monash IVF Group Ltd (ASX: MVF<\/a>) <\/p>\n

The Monash IVF share price is steady on Monday at 71 cents.<\/p>\n

This ASX 200 healthcare share has defied sector trends to rise 12.7% over 12 months. <\/p>\n

But it’s been a bumpy road, as the chart below shows, and Christopher Watt from Bell Potter gives the stock a sell rating. <\/p>\n

Watt said:\u00a0<\/p>\n

The fertility services company recently downgraded fiscal year 2026 guidance. It now expects underlying net profit after tax to range between $17 million and $18 million. <\/p>\n

Across the Australian market, stimulated cycle volumes were down 4.7 per cent on a rolling three month basis to the end of April when compared to the prior corresponding period. <\/p>\n

Cost-of-living pressures and declining birth rates are structural headwinds for the whole industry. <\/p>\n

New leadership has a genuine reset opportunity, but until there’s evidence of an industry-wide recovery, I remain cautious.<\/p>\n","protected":false},"excerpt":{"rendered":"Healthcare\u00a0shares\u00a0are underperforming today, down 0.33%, while the benchmark S&P\/ASX 200 Index (ASX: XJO) is 0.15% lower. Healthcare led…\n","protected":false},"author":2,"featured_media":505088,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46],"class_list":["post-505087","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/505087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=505087"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/505087\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/505088"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=505087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=505087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=505087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}